SCHEMBL2583420

SCHEMBL2583420

O=C(Nc1ccc(N2CCN(C(=O)O)CC2)cc1)c1ccccc1I

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 3/20 0.60
MEN1 O00255 1/20 0.60
KMT2A Q03164 1/20 0.60
RAB9A P51151 9/20 0.56
NPC1 O15118 8/20 0.56
MAPT P10636 10/20 0.56
LMNA P02545 3/20 0.56
SMN1; SMN2 Q16637 6/20 0.54
ALDH1A1 P00352 4/20 0.54
TP53 P04637 2/20 0.54
MCL1 Q07820 1/20 0.54
TSHR P16473 1/20 0.54
GAA P10253 2/20 0.53
MAPK1 P28482 2/20 0.53
L3MBTL1 Q9Y468 2/20 0.53
NPSR1 Q6W5P4 1/20 0.53
PKM P14618 1/20 0.51
NFKB1 P19838 1/20 0.51
NFKB2 Q00653 1/20 0.51
RELA Q04206 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15943476 0.84 ME2 (0.61) TDP1MEN1KMT2ARAB9ANPC1
SCHEMBL2585345 0.83 NPY2R (0.61) TDP1MEN1KMT2ARAB9ANPC1
SCHEMBL2586346 0.83 MT-CO2 (0.59) TDP1MEN1KMT2ARAB9ANPC1
SCHEMBL5131436 0.80 NPY2R (0.77) TDP1MEN1KMT2ARAB9ANPC1
Benodanil SCHEMBL18736 0.77 MEN1 (1.00) TDP1MEN1KMT2ARAB9ANPC1
Benodanil SCHEMBL29402073 0.77 MEN1 (1.00) TDP1MEN1KMT2ARAB9ANPC1
SCHEMBL7603598 0.76 NPY2R (0.55) TDP1MEN1KMT2ARAB9ANPC1
SCHEMBL5183604 0.75 NPC1 (0.64) MEN1KMT2ARAB9ANPC1MAPT
SCHEMBL5184734 0.75 NPC1 (0.64) MEN1KMT2ARAB9ANPC1MAPT
SCHEMBL5184503 0.74 KMT2A (0.75) MEN1KMT2ARAB9ANPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8354402-B2 Polyarylcarboxamides useful as lipid lowering agents JANSSEN PHARMACEUTICA N.V. (BE) 2013-01-15 US disclosed
US-20110269747-A1 POLYARYLCARBOXAMIDES USEFUL AS LIPID LOWERING AGENTS MEERPOEL LIEVEN 2011-11-03 US disclosed
EP-1317431-B1 POLYARYLCARBOXAMIDES USEFUL AS LIPID LOWERING AGENTS JANSSEN PHARMACEUTICA NV (BE) 2010-10-20 EP disclosed
US-7528154-B2 Polyarylcarboxamides useful as lipid lowering agents JANSSEN PHARMACEUTICAL N.V. (BE) 2009-05-05 US disclosed
US-20080125412-A1 POLYARYLCARBOXAMIDES USEFUL AS LIPID LOWERING AGENTS MEERPOEL LIEVEN 2008-05-29 US disclosed
US-7253157-B2 Polyarylcarboxamides useful as lipid lowering agents JANSSEN PHARMACEUTICA N.V. (BE) 2007-08-07 US disclosed
EP-1806341-A2 (+)Phenyl-(4-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-piperidin-1-yl)-acetic acid methyl ester as lipid lowering agent JANSSEN PHARMACEUTICA N.V. (BE) 2007-07-11 EP disclosed
US-20070082888-A1 POLYARYLCARBOXAMIDES USEFUL AS LIPID LOWERING AGENTS MEERPOEL LIEVEN 2007-04-12 US disclosed
US-7169796-B2 Polyarylcarboxamides useful as lipid lowering agents JANSSEN PHARMACEUTICA N.V. (BE) 2007-01-30 US disclosed
US-20060241113-A1 Polyarylcarboxamides useful as lipid lowering agents MEERPOEL LIEVEN 2006-10-26 US disclosed
US-20050159402-A1 Polyarylcarboxamides useful as lipid lowering agents MEERPOEL LIEVEN (BE) 2005-07-21 US disclosed
US-6878724-B2 Polyarylcarboxamides useful as lipid lowering agents JANSSEN-PHARMACEUTICA N.V. (BE) 2005-04-12 US disclosed
US-20040014971-A1 Polyarylcarboxamides useful as lipid lowering agents JANSSEN PHARMACEUTICA N.V. (BE) 2004-01-22 US disclosed
EP-1317431-A2 POLYARYLCARBOXAMIDES USEFUL AS LIPID LOWERING AGENTS JANSSEN PHARMACEUTICA N.V. (BE) 2003-06-11 EP disclosed
WO-2002020501-A2 POLYARYLCARBOXAMIDES USEFUL AS LIPID LOWERING AGENTS JANSSEN PHARMACEUTICA N.V. (BE) 2002-03-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050159402-A1 Polyarylcarboxamides useful as lipid lowering agents LIPC, PNLIP, APOB TDP1 3375/4885MEN1 1707/4885KMT2A 1683/4885
US-20080125412-A1 POLYARYLCARBOXAMIDES USEFUL AS LIPID LOWERING AGENTS LIPC, PNLIP, APOB TDP1 3375/4885MEN1 1707/4885KMT2A 1683/4885
US-20060241113-A1 Polyarylcarboxamides useful as lipid lowering agents LIPC, PNLIP, APOB TDP1 3375/4885MEN1 1707/4885KMT2A 1683/4885
US-20110269747-A1 POLYARYLCARBOXAMIDES USEFUL AS LIPID LOWERING AGENTS LIPC, PNLIP, APOB TDP1 3375/4885MEN1 1707/4885KMT2A 1683/4885
US-20040014971-A1 Polyarylcarboxamides useful as lipid lowering agents SREBF1, LIPC, CPT1A TDP1 1806/4885MEN1 846/4885KMT2A 2044/4885
US-20070082888-A1 POLYARYLCARBOXAMIDES USEFUL AS LIPID LOWERING AGENTS LIPC, PNLIP, APOB TDP1 3375/4885MEN1 1707/4885KMT2A 1683/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.